Association of biomarkers with NRM at treatment. (A) The proportion of patients in each risk group in classic acute GVHD at onset of treatment were AA1, 56.8% (591 of 1041) and AA2/3, 43.2% (450 of 1041). The cumulative incidences of NRM at 6 months were 7.4% (95% CI, 5.5-9.8) and 25.9% (95% CI, 22.0-30.1) in AA1 and AA2/3 groups (P < .001). (B) The proportion of patients in each risk group in late acute GVHD were 48.3% (43/89) and 51.7% (46/89) for AA1 and AA2/3 groups. The cumulative incidences of NRM at 6 months were 4.9% (95% CI, 0.9-14.7) and 42.2% (95% CI, 27.1-56.6), respectively (P < .001).